|
- A Randomized Controlled Trial of Thoracentesis in Acute Heart . . .
BACKGROUND:TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion–Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients
- Effective bridging therapy can improve CD19 CAR-T outcomes . . .
Bridging therapy (BT) is safe, and complete partial response to BT confers a 42% reduction in risk of progression death after CD19CAR-T therapy Good response to BT is twice as likely with polatuzumab than with other modalities and is particularly
- Brexucabtagene autoleucel for the treatment of relapsed . . .
Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the bruton tyrosine kinase inhibitors in the relapsed refractory (R R) disease setting
- International myeloma working group immunotherapy committee . . .
The subsequent phase 3 CARTITUDE-4 trial compared the efficacy of cilta-cel versus certain SOC regimens in patients with lenalidomide-refractory MM who had received 1-3 prior lines of therapy; of
- Current management of refractory overactive bladder
Overactive bladder (OAB) is a common condition affecting one-sixth to one-fifth of the global population The treatment of refractory OAB remains a challenge for urologists Current treatment options include the use of combination therapy with antimuscarinic agents and beta-3 adrenoceptor agonists, …
- PowerPoint Presentation
The International League Against Epilepsy (ILAE) defines drug resistant epilepsy (refractory epilepsy) as the following: When a person has failed to become and stay seizure free with adequate trials of 2 AED’s
|
|
|